Cabaletta Bio financials
$1.98−1.00%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating income | -$52.1M | -$44.0M | -$42.6M | -$46.6M | -$46.0M | -$37.1M | -$33.8M | -$33.0M | -$30.3M | -$28.0M | -$23.1M | -$18.7M |
| Net income | -$51.0M | -$43.5M | -$41.9M | -$44.9M | -$45.1M | -$35.9M | -$32.5M | -$30.6M | -$27.6M | -$24.3M | -$20.9M | -$16.4M |
| Net margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Diluted EPS | $-0.34 | $-0.39 | $-0.40 | $-0.44 | $-0.73 | $-0.71 | $-0.65 | $-0.62 | $-0.56 | $-0.51 | $-0.41 | $-0.37 |
| EBITDA | -$51.7M | -$43.6M | -$42.3M | -$46.2M | -$45.5M | -$36.7M | -$33.3M | -$32.6M | -$29.9M | -$27.6M | -$22.8M | -$18.3M |
| Operating cash flow | -$41.5M | -$42.6M | -$35.3M | -$34.5M | -$30.4M | -$30.8M | -$23.1M | -$20.3M | -$20.8M | -$24.0M | -$16.4M | -$12.6M |
| Free cash flow | -$41.5M | -$42.6M | -$35.5M | -$34.6M | -$30.6M | -$31.6M | -$23.5M | -$20.6M | -$21.6M | -$24.8M | -$16.6M | -$12.7M |
| Diluted shares | 151.2M | 112.0M | 104.7M | 102.3M | 61.9M | 50.7M | 49.9M | 49.5M | 49.4M | 49.3M | 50.4M | 44.0M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $225.1M | $116.6M | $83.0M | $60.2M | $145.6M | $131.8M |
| Short-term investments | $0.00 | $0.00 | $50.6M | $99.7M | $49.1M | $0.00 |
| Total debt | $20.0M | $24.0M | $23.6M | $22.2M | $20.3M | $23.3M |
| Total assets | $256.7M | $148.1M | $165.1M | $189.8M | $224.5M | $165.1M |
| Total liabilities | $46.1M | $44.8M | $53.0M | $50.3M | $46.0M | $43.6M |
| Shareholders' equity | $210.6M | $103.3M | $112.1M | $139.5M | $178.5M | $121.6M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology